Retraction Note: RGD peptide-pegylated PLLA nanoparticles containing epirubicin hydrochloride exhibit receptor-dependent tumor trafficking in vitro and in vivo

Ping Huang¹ • Jun Wu² • Ximeng Li¹ • Xiaozheng Liu¹ • Yinghuan Li¹ • Guohui Cui¹

Published online: 2 February 2016
© Springer Science+Business Media New York 2016

Erratum to: Pharm Res
DOI: 10.1007/s11095-015-1625-2

As per the request of the author, this article has been retracted due to data that is unable to be confirmed.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s11095-015-1625-2>.

✉ Yinghuan Li
Yinghua.Li@asu.edu

✉ Guohui Cui
cuiguohui@bjmu.edu.cn; cgh@ccmu.edu.cn

¹ School of Chemical Biology and Pharmaceutical Science, Capital Medical University, Beijing, China

² College of Pharmacy, University of South Carolina, Columbia, SC, USA